A process for synthesizing antifolate compounds is disclosed. The process includes cyclization of a readily available starting reagent, followed by one or more coupling steps to produce compounds that mimic folic acid. The compounds synthesized have commercial use as drugs in oncology, inflammatory disease, and other medical fields.
STABLE CRYSTALLINE POLYMORPHS OF THE DIPOTASSIUM SALT OF (S) -2- {4- [2- (2, 4-DIAMIN0-QUINAZ0LIN-6-YL) -ETHYL]-BENZOYLAMINO} -4-METHYLEN -PENTA NEDIOIC ACID
申请人:Chelsea Therapeutics, Inc.
公开号:EP2451788A1
公开(公告)日:2012-05-16
STABLE CRYSTALLINE SALTS OF ANTIFOLATE COMPOUNDS
申请人:Pimplaskar Harish K.
公开号:US20110124650A1
公开(公告)日:2011-05-26
The present invention provides stable crystalline polymorphic forms of antifolate compounds, particularly (S)-2-4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-pentanedioic acid, dipotassium salt, and methods of preparation thereof The polymorphs may be in the form of hydrates. The invention further provides pharmaceutical compositions comprising the polymorphs and methods of treatment using the polymorphs. The polymorphs are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis, and the polymorphs may be administered alone in or combination with on or more further active agents.
ANTIFOLATE COMBINATIONS
申请人:Roberts Michael J.
公开号:US20120142692A1
公开(公告)日:2012-06-07
The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of further conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis.